Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Bennett

Showing results (11-20 of 331) with videos related to

Pageof 34
Sort By:
Cancer Treatment and Research|November 30, 2022
Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at WorkCharles L Bennett, Shamia Hoque
Cancer Treatment and Research|November 30, 2022
Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature BirthOscar Champigneulle, Charles L Bennett
Cancer Treatment and Research|November 30, 2022
Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug AdministrationPaul Ray, Charles L Bennett
Archives of Internal Medicine|October 24, 2012
Will newer anticoagulants improve therapy persistence?Whitney Maxwell, Charles L Bennett
Urology|February 7, 2021
EDITORIAL COMMENTCharles L Bennett, Oliver Sartor
Urology|December 23, 2014
Editorial commentOliver Sartor, Charles L Bennett
Oncology (Williston Park, N.Y.)|February 26, 2003
Evaluating the total costs of cancer. The Northwestern University Costs of Cancer ProgramElizabeth A Calhoun, Charles L Bennett
Cancer|October 26, 2005
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paidJonathan R Nebeker, Charles L Bennett
Urology|August 11, 2010
Editorial commentPaul S Ray, Charles L Bennett
Seminars in Thrombosis and Hemostasis|November 1, 2012
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)Whitney D Maxwell, Charles L Bennett
Pageof 34

Showing results (11-20 of 331) with videos related to

Sort By:
Pageof 34
Cancer Treatment and Research|November 30, 2022
Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at WorkCharles L Bennett, Shamia Hoque
Cancer Treatment and Research|November 30, 2022
Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature BirthOscar Champigneulle, Charles L Bennett
Cancer Treatment and Research|November 30, 2022
Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug AdministrationPaul Ray, Charles L Bennett
Archives of Internal Medicine|October 24, 2012
Will newer anticoagulants improve therapy persistence?Whitney Maxwell, Charles L Bennett
Urology|February 7, 2021
EDITORIAL COMMENTCharles L Bennett, Oliver Sartor
Urology|December 23, 2014
Editorial commentOliver Sartor, Charles L Bennett
Oncology (Williston Park, N.Y.)|February 26, 2003
Evaluating the total costs of cancer. The Northwestern University Costs of Cancer ProgramElizabeth A Calhoun, Charles L Bennett
Cancer|October 26, 2005
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paidJonathan R Nebeker, Charles L Bennett
Urology|August 11, 2010
Editorial commentPaul S Ray, Charles L Bennett
Seminars in Thrombosis and Hemostasis|November 1, 2012
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)Whitney D Maxwell, Charles L Bennett
Pageof 34